Comparative Pharmacology
Head-to-head clinical analysis: BRONKAID MIST versus XOPENEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BRONKAID MIST versus XOPENEX.
BRONKAID MIST vs XOPENEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Epinephrine, the active ingredient, is a direct-acting sympathomimetic amine that stimulates alpha- and beta-adrenergic receptors. Beta-2 receptor activation in bronchial smooth muscle causes bronchodilation. Alpha receptor activation causes vasoconstriction, reducing mucosal edema.
Selective beta-2 adrenergic receptor agonist that relaxes bronchial smooth muscle by increasing intracellular cyclic AMP levels.
2 inhalations (200 mcg per inhalation) every 4 hours as needed for bronchospasm. Maximum 12 inhalations in 24 hours.
Nebulized solution: 0.63 mg or 1.25 mg 3 times daily every 6-8 hours; metered-dose inhaler: 2 inhalations (90 mcg per inhalation) 3 times daily every 6-8 hours.
None Documented
None Documented
Terminal elimination half-life: 3-6 hours; clinical context: shorter half-life in children, prolonged in hepatic impairment; requires frequent dosing
Terminal elimination half-life: 3.3-4.0 hours in adults. Clinically, twice-daily dosing is not recommended due to shorter half-life; every 4-6 hour dosing is standard for acute bronchodilation.
Renal: 40-70% unchanged; fecal: minor (biliary) <5%
Renal: 80-100% as unchanged drug and metabolites (approximately 60% as unchanged levalbuterol, 20% as inactive sulfate conjugate). Fecal: <5%.
Category C
Category C
Bronchodilator
Bronchodilator